Research/key-initiatives/ras/outreach/reference-reagents
Contents
RAS Reference Reagents
RAS Initiative researchers have developed unique reagents at the FNLCR. We hope that by widely distributing these to the larger RAS community, we can increase the efficiency of all research on RAS.
For further information on RAS Reference Reagents, contact Dominic Esposito.
Complete Set of RAS Pathway Genes
A community conversation highlighted 180 genes considered to comprise the core of the RAS pathway. Now the RAS Reference Reagents program has used data from The Cancer Genome Atlas to construct entry clones of each gene representing the dominant transcript across more than 30 human cancers. All 180 genes (both stop and no-stop versions) are available through AddgeneExit Disclaimer.
Reagents for Producing Fully-Processed KRAS 4B Protein
FNL scientists recently published a description of the cloning, expression, and characterization of fully-processed (farnesylated, carboxymethylated) KRAS 4b protein (Gillette WK, et al., Sci Rep. 2015, 5:15916. doi: 10.1038/srep15916Exit Disclaimer). Both the baculovirus (expresses KRAS 4b and the human farnesyltransferase) and the baculovirus host strain (Hi5, Trichoplusia ni) used in the FNL procedure are available under a Material Transfer Agreement.
Contact Dominic Esposito for further information.
Wild-Type and Mutant KRAS, HRAS, and NRAS Genes
A collection of 60 wild-type and mutant RAS genes as Gateway entry clones is now available through AddgeneExit Disclaimer. The collection comprises wild-type HRAS, NRAS, KRAS4a and KRAS4b genes, and mutant KRAS4b (N=36), KRAS4a (N=6), HRAS (N=7) and NRAS (N=7) genes. All the clones are fully sequenced and have the same context to enable optimal correlation of phenotype with genotype.
RAS Cell Lines
Two sets of RAS cell lines have been extensively characterized by RAS Initiative scientists, "RASless" mouse embryonic fibroblasts (MEFs), and patient-derived cancer cell lines that express mutant KRAS genes.
